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ABSTRACT 
Introduction: Reduced skeletal muscle function and cognitive performance are 
common extrapulmonary features in Chronic Obstructive Pulmonary Disease (COPD) 
but their connection remains unclear. Whether presence or absence of skeletal muscle 
dysfunction in COPD patients is linked to a specific phenotype consisting of reduced 
cognitive performance, comorbidities and nutritional and metabolic disturbances needs 
further investigation. 
Methods: Thirty-seven patients with COPD (grade II-IV) were divided into two 
phenotypic cohorts based on the presence (COPD dysfunctional, n=25) or absence 
(COPD functional, n=12) of muscle dysfunction. These cohorts were compared to 28 
healthy, age matched controls. Muscle strength (dynamometry), cognitive performance 
(Trail Making Test and STROOP Test), body composition (Dual-energy X-Ray 
Absorptiometry), habitual physical activity, comorbidities and mood status 
(questionnaires) were measured. Pulse administration of stable amino acid tracers was 
performed to measure whole body production rates. 
Results: Presence of muscle dysfunction in COPD was independent of muscle mass or 
severity of airflow obstruction but associated with impaired STROOP Test performance 
(p=0.04), reduced resting O2 saturation (p=0.003) and physical inactivity (p=0.01), and 
specific amino acid metabolic disturbances (enhanced leucine (p=0.02) and arginine 
(p=0.06) production). In contrast, COPD patients with normal muscle function presented 
with anxiety, increased fat mass, plasma glucose concentration, and metabolic 
syndrome related comorbidities (hypertension and dyslipidemia). 
Conclusion: COPD patients with muscle dysfunction show characteristics of a 
cognitive - metabolic impairment phenotype, influenced by the presence of hypoxia, 
whereas those with normal muscle function present a phenotype of metabolic syndrome 
and mood disturbances. 
Key Words: COPD, muscle strength, cognition, phenotype, metabolism 
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Skeletal muscle dysfunction is an extrapulmonary feature of Chronic Obstructive 
Pulmonary Disease (COPD){Jaitovich, 2018, 175-186;Gea, 2015, E418-38}, negatively 
affecting their physical activity, quality of life, and mortality{Maltais, 2014, e15-62}. 
Muscle dysfunction in COPD can be present independent of lung function 
severity{Swallow, 2007, 115-20} and muscle mass loss, indicative of muscle myopathy. 
Moreover, cognitive impairment{Schure, 2016, 46-52} and mood disturbances{Ouellette, 
2017, 639-650} are present in COPD at higher rates than in the general (non-COPD) 
population{Divo, 2015, 640-50}. A link between the muscle and brain has been 
observed in older adults as reflected by the simultaneous decline in both muscle 
strength and cognitive function{Raji, 2005, 1462-8;Alfaro-Acha, 2006, 859-65}, and the 
fact that exercise training can improve cognitive function{Pereira, 2011, 279-85;Teixeira, 
2013, 148-156}. Presence of physical inactivity and systemic inflammation in COPD are 
known risk factors for both physical and cognitive dysfunction{Barreiro, 2015, 413-
26;Plassman, 2010, 182-93;Degens, 2010, 28-38;Baierle, 2015, 1-12}. In addition, 
hypoxia may contribute to the high prevalence of muscle dysfunction and impaired 
cognitive performance in COPD, as hypoxia is known to increase oxidative stress and 
inflammation, leading to signaling remodeling of smooth muscle in COPD{Coimbra-
Costa, 2017, 216-225;Wiegman, 2015, 769-80} and physical damage of brain 
tissue{Ryu, 2013, 357-66}. In line, COPD patients on long-term oxygen therapy 
exhibited more cognitive impairment than non-oxygen users despite similar disease 
severity{Karamanli, 2015, 2087-94}. These physiological changes suggest a connection 
between muscle and cognitive dysfunction in patients with COPD but whether there is a 
direct link remains unclear.  
Both fibre type shifts towards a predominantly type II composition and 
disturbances in protein and amino acid metabolism (e.g. glutamate and the branched 
chain amino acids){Engelen, 2001, 859-64} in COPD may contribute to the reduced 
functional metabolic capacity of the limbs{Ciciliot, 2013, 2191-2199} in these patients. 
Whether disturbances in the metabolism of these as well as other amino acids 
(including tryptophan as precursor of serotonin){Lieben, 2018, 321-328}) provide a 
direct metabolic link between the presence of muscle and cognitive dysfunction in 
COPD as recently suggested{Gosker, 2019, 915} deserves further investigation. We 
hypothesize that particularly COPD patients with muscle dysfunction are at risk for 
cognitive impairment due to the presence of disease related risk factors such as 
hypoxia, inflammation, and physical inactivity contributing to specific disturbances in 
amino acid metabolism.  
In the present study, we examined a heterogeneous group of moderate to severe 
COPD patients who were stratified based on the presence/absence of muscle 
dysfunction into dysfunctional and functional COPD cohorts. Cognitive performance, 
mood status, disease severity, habitual dietary intake and physical activity, 
comorbidities, protein and amino acid metabolism, and body composition were 
examined in both groups and compared to a group of healthy age-matched subjects 
from the MEDIT (MEtabolism of Disease with Isotope Tracers) trial, to examine whether 
presence or absence of skeletal muscle dysfunction in COPD patients is linked to a 
specific phenotype.  
 
MATERIALS AND METHODS 
Subjects 
We studied 37 older adults with a clinical diagnosis of moderate to severe airflow 
obstruction (grade II-IV), according to the established Global Initiative for Chronic 
Obstructive Pulmonary Disease GOLD guidelines and 28 healthy age matched 
subjects. The participants were recruited via advertisements in the surrounding 
hospitals and local community. Patients were clinically stable and not suffering from an 
acute exacerbation or infection and their disease was stable for the previous four 
weeks. Exclusion criteria were pre-existent untreated metabolic or renal disease, 
malignancy, recent surgery, and use of systemic corticosteroids one month prior to the 
study. Medical history and medication use were assessed as part of the screening 
process. Written informed consent was obtained from all subjects, and the study was 
approved by the Institutional Review Board of Texas A&M University. 
 
Anthropometrics, body composition, and lung function 
Body weight and height were measured by a digital beam scale and stadiometer, 
respectively, and regional values for fat mass and fat-free mass were obtained from all 
subjects while in supine position, by Dual-Energy X-ray Absorptiometry (DXA) (Hologic 
QDR 4500/ Version 12.7.3.1 (Bedford, MA)). Anthropometric and body composition 
measures were standardized for height (kg/m2), to obtain BMI, FFM index (FFMI), FM 
index (FMI), and appendicular skeletal muscle index (ASMI). Post-bronchodilator forced 
expiratory volume in 1 second (FEV1) was assessed with the highest value from ≥ 3 
technically acceptable maneuvers. 
 
Muscle function testing 
The single leg muscle function test was completed with the right limb, using an 
isokinetic dynamometer (Isokinetic International, Chattanooga, TN). In a seated position 
the trunk, pelvis, and right thigh were secured using straps to prevent body movement. 
Standardized, intense verbal encouragement was given to all subjects throughout the 
test. All tests were performed by the same researcher to secure consistency. After a 
warm-up (10 low-effort repetitions), peak leg torque was assessed at 60°/sec by 5 
maximal extension-flexion cycles, each cycle followed by ten seconds of rest.    
Handgrip strength was assessed by Vernier Hand Dynamometry (Vernier 
Software and Technology, Beaverton, OR) with subjects in a seated position with their 
dominant arm unsupported and elbow flexed at 90 degrees. Subjects were encouraged 
to squeeze the dynamometer maximally for 5 seconds with 60 seconds rest between 
each trial to obtain at least 3 reliable measurements.   
Maximal expiratory pressure (MEP) and inspiratory pressure (MIP) as measures 
of respiratory muscle strength were assessed by determining the maximal value of at 
least 3 reliable attempts using a hand-held mouth pressure device (Micro Respiratory 
Pressure Meter (RPM)) with at least 1 minute of rest between each attempt. 
 
Cognitive testing and questionnaires 
Trail Making Test (TMT) was used to assess visual-motor tracking skills and 
psychomotor speed. The subjects had to connect consecutive numbers randomly 
arranged on a page (TMT- Pt A) or consecutive numbers and letters in alternating order 
(TMT- Pt B).  
Stroop Color Word Test (SCWT) was used to measure executive functioning and 
cognitive flexibility as response inhibition for colored printed words. The completion 
times (sec) and number of errors were recorded for each part. Mood status (depression 
and anxiety) was assessed by the Hospital Anxiety and Depression Scale (HADS). 
Habitual dietary intake was assessed using 24-hour dietary recall while daily 
physical activity level was measured by the Physical Activity Scale for the Elderly 
questionnaire (PASE). The Charlson index was used for the assessment of concomitant 
comorbidities. 
 
Stable isotope administration by IV pulse 
A peripheral line was placed in a superficial dorsal vein of the hand or lower arm for 
infusion of a bolus of stable tracers and subsequent blood sampling. The hand was 
placed in a thermostatically controlled hot box (internal temperature: 60°C), a technique 
to mimic direct arterial sampling. After a venous blood sample was collected to measure 
baseline enrichment, an intravenous pulse administration of a cocktail of stable 
tracers{Deutz, 2018, 167-178} was given (Figure 1) (Cambridge Isotopic Laboratories, 
Woburn, MA, USA). Arterialized-venous blood was sampled at multiple time points until 
four hours after pulse administration.  
Biochemical analysis and calculations 
Arterialized-venous blood was put in Li-heparinized (Becton Dickinson Vacutainer 
system, Franklin Lakes, New Jersey, USA), immediately put on ice to minimize 
enzymatic reactions, and centrifuged to obtain plasma. A part of the plasma was 
aliquoted into tubes with trichloroacetic acid for denaturation of proteins. Samples were 
immediately frozen and stored at -80°C until further analysis. Tracer enrichments 
[tracer:tracee ratio (TTR)] and plasma amino acid concentrations were analyzed batch-
wise by LC-MS/MS or GC-MS/MS as previously reported{Jonker, 2016, 1458-64;Deutz, 
2018, 167-178}. Whole body production (WBP) rates of various amino acids 
(e.g.leucine, tryptophan, glutamate, glutamine, glycine, arginine, citrulline) were 




We determined gender specific normal values for single leg and handgrip strength 
based on the measurements obtained from 38 (18F/20M) healthy older subjects who 
visited CTRAL in the past 3 years. These values were used to create two COPD 
cohorts: COPD muscle functional (> 1SD below normal value for handgrip and/or leg 
strength, n=12) and COPD dysfunctional (< 1SD below normal value, n=25). Results 
are expressed as mean ± standard error (SE). The unpaired Student’s t test was used 
to determine differences between healthy older adults and the total COPD group. One-
way Analysis of variance (ANOVA), followed by Bonferroni multiple comparison test, 
was used to determine differences between healthy older adults, COPD muscle 
functional, and COPD dysfunctional cohorts. Pearson’s correlation analysis was used to 
determine relationships between muscle function and disease severity, cognitive 
performance, mood status, habitual dietary intake and physical activity, comorbidities, 
protein and amino acid metabolism, and body composition variables. The statistical 
package within Graphpad Prism (Version 8.2.0, GraphPad Software Inc, San Diego, 
USA) was used for data analysis. The level of significance was set a priori at p<0.05. 
RESULTS 
Body composition, disease severity, and habitual dietary intake 
General subject characteristics are presented in Table 1. The muscle dysfunction COPD 
cohort was older than the functional and tended to be older (p=0.055) than the healthy 
group. There was a slight gender skew in the functional cohort with 75% being female as 
compared to 46 and 48% in healthy and dysfunctional, respectively. BMI tended to be 
higher in the functional COPD group than in the other two groups but no differences 
were found in lean mass (Figure 2a). The functional COPD group tended to have more 
total fat mass compared to the healthy (p=0.058) with increased percentage android and 
gynoid fat mass over the dysfunctional group. Charlson comorbidity index was elevated 
in both COPD cohorts. No differences in severity of airflow obstruction were seen 
between COPD cohorts (Figure 2b) except for a trend towards a lower resting oxygen 
saturation in the dysfunctional group. Number of oxygen users (defined as O2 use 
continuously, at night or as needed) was 52% and 33% in the dysfunctional and 
functional COPD group, respectively. Daily dietary caloric and macronutrient intake was 
similar across all groups for all nutrients measured except for lower fiber intake in both 
COPD cohorts.  
 
Muscle function and physical activity 
Maximal handgrip and leg strength were lower in the COPD total group (Table 2). In-line 
with group allocation, leg strength was lower in the COPD dysfunctional group than in 
the healthy and functional COPD cohort, but no difference was found between the 
healthy and functional COPD groups. Leg strength corrected for total lean mass, as a 
measure of muscle quality, was 30% lower in the COPD dysfunctional group (Table 2). 
Inspiratory and expiratory muscle strength along with daily physical activity were lower in 
COPD total as compared to healthy, due to lower values in the dysfunctional COPD 
cohort. 
 
Cognitive performance and mood status 
SCWT assessed executive functioning and cognitive flexibility while TMT evaluated 
visual-motor tracking skills and psychomotor speed (Table 2, Figure 3). The total COPD 
group performed significantly slower on all three parts of the SCWT in addition to the 
TMT parts, however after stratification, significance only remained for the dysfunctional 
COPD cohort, with a trend towards a difference between functional and dysfunctional for 
TMT-Pt A. The functional and dysfunctional COPD cohorts reported to be more 
depressed than the healthy group with the functional COPD cohort being most anxious.  
 
Protein and amino acid metabolism  
No differences were found in plasma amino acid concentrations among the healthy and 
COPD groups (Table 3), although both COPD cohorts had elevated plasma hs-CRP 
levels, whereas plasma glucose levels were increased only in the functional COPD 
cohort. Whole body production of the Branched-Chain Amino Acid (BCAA) leucine was 
elevated in the dysfunctional cohort compared to healthy while the amino acids citrulline 
and arginine tended to be increased (p=0.02, p=0.05, p=0.06, respectively, Table 4). No 
differences were observed in the production rates of the remaining amino acids.  
 
Relationships between muscle function, cognitive performance, and metabolic 
markers in COPD 
Muscle function 
Reduced single leg strength per kilogram lean mass in COPD was associated with 
cognitive dysfunction as displayed by increased time to completion for SCWT-Pt 3 
(Figure 5a) and TMT-Pt B (Figure 5b) and lower plasma tryptophan concentration 
(Figure 4d). Higher single leg strength alone was associated with a higher plasma 
glutamate concentration (r:0.47, p<0.01) and lower values for glycine whole body 
production (r:-0.40, p<0.05) and plasma concentration (r:-0.40, p<0.05). 
Cognitive performance 
Increased time to completion for SCWT-Pt3 was associated with metabolic disturbances 
as reflected by lower values for total plasma concentration of Branched-Chain Keto 
Acids (BCKAsum) (r:-0.43, p<0.05). Likewise, TMT-Pt B was associated with lower 
values for plasma concentrations of LEU (r:-0.48, p<0.01), VAL (r:-0.40, p<0.05), 
BCAAsum (Figure 4c), and BCKAsum (r:-0.38, p<0.05).   
 
DISCUSSION 
We studied whether COPD patients are characterized by distinct phenotypes based on 
the presence/absence of muscle dysfunction relative to healthy, age-matched controls. 
We found that COPD patients with muscle dysfunction are characterized by decreased 
cognitive performance, mood status, physical activity, and transcutaneous O2 
saturation. COPD patients with preserved muscle function presented characteristics of 
metabolic syndrome and mood disturbances. Presence of muscle dysfunction in COPD 
was independent of muscle mass loss and severity of airflow obstruction. 
 
Profile of COPD patients with muscle dysfunction phenotype 
Our muscle dysfunction COPD cohort displayed systemic weakness as reflected by 
concurrent weakness of the upper, lower, and respiratory muscles but no differences 
were seen in muscle mass across the study groups. Muscle weakness despite 
preserved muscle mass has been seen in COPD patients previously and supports a 
more rapid development of muscle myopathy before atrophy develops{Jaitovich, 2018, 
175-186}. Muscle quality, i.e. strength relative to size, was >30% lower in our 
dysfunctional cohort as compared to controls. As muscle mass can not be used as a 
proxy of muscle function in COPD and muscle dysfunction is a predictor of morbidity 
and mortality in these patients, incorporation of muscle function testing to identify 
muscle weakness is therefore of critical importance. A recent review highlighted the 
combination of etiological factors (i.e. inactivity, comorbidities, inflammation) and 
biological mechanisms (i.e. oxidative stress, proteolysis) which promote dysfunction of 
ventilatory and peripheral muscles in COPD{Barreiro, 2016, 297-311}. A holistic 
approach to prevent and reverse muscle dysfunction in COPD is therefore 
required{Jaitovich, 2018, 175-186}, in which the treatment strategy focuses on 
employing resistance and endurance exercise in combination with optimized diet and 
medications.  
● Reduced cognitive function  
Patients with muscle dysfunction showed reduced time to completion and increased 
number of errors across both the SCWT and TMT, which are reflective of impaired 
executive functioning with cognitive inflexibility and reduced psychomotor speed, 
respectively. Decreased productivity on processing-speed tasks such as the SCWT is 
an important indicator of bradyphrenia characterized by reduced processing speed, 
inattentiveness, delayed response and psychomotor impairment. Disturbances in mood 
state were also seen in our muscle dysfunctional cohort in agreement with previous 
studies reporting the severity of anxiety and depression increases with the appearance 
of COPD symptoms and reduction in daily physical activity{Miravitlles, 2014, 259-65}. 
Previous studies showed that 18-35% of COPD patients present with cognitive 
impairment{Ouellette, 2017, 639-650}. Patients with concomitant muscle and cognitive 
dysfunction are in danger of being overlooked as cognitive impairment is a potential 
exclusion criterion for pulmonary rehabilitation{Cleutjens, 2017, 420-426}.  
In a longevity-based study, a strong association was observed between a 
reduction in cognitive function and handgrip strength in older adults, with the lowest 
cognitive performers having the steepest decline in handgrip strength{Raji, 2005, 1462-
8}. The authors proposed inflammation as a shared factor affecting both cognition and 
muscle function. In a follow up study using HEPESE data, the same trend was seen 
over a 7 year follow up{Alfaro-Acha, 2006, 859-65}. The brain connects cognitive and 
muscle function via the central nervous system so a decline in performance of both 
activities may reflect reduced integrity of the nervous system. Shared pathogenic factors 
between cognitive and muscle function e.g. oxidative stress, inflammatory markers, and 
sex steroids further link these functional parameters{Rosano, 2005, 8-14}. 
Interestingly, older adults completing 16 weeks of exercise training improved 
cognitive function independent of sufficient cardiovascular stimulus to affect aerobic 
capacity or specific cognitive training{Teixeira, 2013, 148-156}. Enhanced cerebral 
blood flow, synthesis of neurotransmitters, or regulation of neurotrophic factors are 
possible causes of this concomitant improvement. As 6-min walk distance is positively 
associated with cognitive function in COPD{Dag, 2016, 1044-50}, our data support the 
inclusion of cognitive assessments in the systemic evaluation of exercise rehabilitation 
strategies. 
 
Disease related factors (systemic inflammation and hypoxemia) to explain the link 
between muscle and cognitive dysfunction in COPD  
Although lung function parameters were comparable between COPD cohorts, resting 
oxygen saturation tended to be lower in COPD patients with muscle dysfunction. 
Additionally, nearly 40% of the muscle dysfunctional patients were oxygen users vs. 
16% of functional. Significant associations were found in our total COPD population 
between oxygen saturation and both cognitive performance and muscle quality, 
confirming previous findings that hypoxia is an important systemic factor underlying 
whole body functional performance in COPD{Kim, 2008, 637-58}. Likewise, low oxygen 
saturation, but not disease severity (e.g. FEV1, BODE), puts COPD patients at an 
increased risk for muscle dysfunction and cognitive impairment{Thakur, 2010, 263-9}, 
as hypoxia increases free radical production, leading to physical damage of both 
muscle{Takabatake, 2000, 1179-1184} and brain tissue{Ryu, 2013, 357-66}. 
Furthermore, higher plasma hs-CRP concentrations were seen in the dysfunctional 
cohort indicative of an increased systemic inflammatory state. Inflammation is one of the 
highest-ranking risk factors for muscle dysfunction{Degens, 2010, 28-38} and cognitive 
impairment{Baierle, 2015, 1-12}. Even slightly increased levels of inflammatory markers 
correlated with reduced cognitive performance in healthy older adults, metabolic 
syndrome and Alzheimer’s disease{Pelgrim, 2019, 99-110}. In skeletal muscle, TNFα, a 
proinflammatory cytokine, can activate the NF-KB pathway thereby upregulating the 
expression of inducible nitric oxide synthase which facilitates the degradation of myosin 
heavy chains through the ubiquitin-proteasome complex{Langen, 2004, 227-237}.  
● Alterations in amino acid metabolism to explain muscle and cognitive 
dysfunction in COPD 
While weight status was not a selection criteria, virtually all our COPD patients 
displayed no markers of cachexia (e.g. reduced BMI or muscle mass) and had an 
adequate daily protein intake (>0.8 g/kg/day). Nevertheless, metabolic alterations of 
amino acids that play a role in muscle contractility were seen. Increased whole body 
production of arginine (precursor of nitric oxide synthesis) and its precursor citrulline 
were observed in the dysfunctional COPD group, in agreement with our previous data in 
COPD{Jonker, 2016, 1458-64}. Reduced muscle function was also associated with 
increased production of glycine (precursor of creatine and glutathione and modulator of 
protein synthesis), and increased plasma concentration of glutamate (neurotransmitter, 
and role in tricarboxylic acid and purine nucleotide cycle). In line with our previous 
findings{Engelen, 2012, 616-624}, we observed an increased whole body production of 
leucine in our muscle dysfunctional cohort. Leucine plays an important role in muscle 
protein degradation and synthesis, and BCAA supplementation in COPD resulted in 
improved cognitive function{Dal Negro, 2012, 67-75}. In line, the impaired cognitive 
performance in our COPD patients with muscle dysfunction was associated with lower 
plasma concentrations of BCAA and BCKA, suggesting a BCAA metabolic link between 
cognitive and muscle dysfunction. Cognitive dysfunction has been associated with 
abnormalities in metabolism of the neuroactive amino acid tryptophan{Lieben, 2018, 
321-328} (precursor of serotonin) in multiple other conditions. Although no significant 
alterations were seen in tryptophan production in our dysfunctional COPD cohort group, 
an association was found between reduced TRP concentrations and muscle strength. In 
line, impaired kynurenine (tryptophan metabolite) metabolism has recently been seen in 
skeletal muscle of COPD patients{Gosker, 2019, 915}, and kynurenine disturbances 
have been associated with impaired cognition and depression{Solvang, 2019, 155-162}. 
Whether there is a direct metabolic link between muscle and cognitive dysfunction via 
alterations in the BCAA and TRP pathways needs further investigation in COPD.  
Profile of COPD patients with normal muscle function  
Patients with normal muscle function had higher BMI due to increased fat mass in both 
the android and gynoid region. Besides increased android fat mass, higher prevalence 
of hypertension and dyslipidemia and increased plasma glucose were found in this 
group, suggesting (early) signs of metabolic syndrome. Metabolic syndrome is of clinical 
importance in COPD as it has a prevalence of >30% in the COPD community with 
higher rates in females{Cebron Lipovec, 2016, 399-406}. Our muscle functional COPD 
cohort presented a phenotype similar to the previously described ‘Metabolic’ 
cluster’{Vanfleteren, 2013, 728-35}, characterized by high prevalence of obesity, 
hypertension, hyperglycemia, and dyslipidemia with comparable lung function. 
Interestingly, no metabolic alterations were found in this cohort.     
Conclusion: Future/past of COPD phenotyping 
In the past decade, approaches to cluster or phenotype COPD subjects have used a 
wide range of methodologies from detailed clinical history to mathematical based 
algorithms{Burgel, 2017, 1701034;Vanfleteren, 2013, 728-35}. Previously these 
analyses have been based on clinically relevant outcomes which are easily obtained in 
a hospital setting, enhancing the potential implementation of these phenotypes for 
treatment, however muscle functional capacity was not always considered. Our data 
show the importance of examining muscle and cognitive function in addition to medical 
history and disease severity, and that two distinct phenotypes exist in COPD based on 
the presence of absence of muscle dysfunction which needs to be considered when 
examining and treating patients with COPD. 
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Figure 1. Overview of study design. Cognitive testing: executive functioning and 
psychomotor speed. Questionnaires: physical activity, mood status, dietary recall. 
Muscle dynamometry: upper and lower limb muscle strength.       
Figure 2. Group characteristics in healthy controls, functional COPD patients, and 
dysfunctional COPD patients. (A) Appendicular skeletal muscle index. (B) Forced 
expiratory volume in 1 second. (C) Leg strength per total kilogram lean body mass. 
Mean ± SE, statistics were obtained by using 1-factor ANOVA to compare differences 
between groups. ****P < 0.0001, ### P <0.001.            
Figure 3. Cognitive function in healthy controls, functional COPD patients, and 
dysfunctional COPD patients. (A) Time to complete SCWT part 3. (B) Errors during 
SCWT part 3. (C) Time to complete TMT part A. (D) Time to complete TMT part B Mean 
± SE, statistics were obtained by using 1-factor ANOVA to compare differences 
between groups. **P < 0.01, **P < 0.05, # P < 0.05.       
Figure 4. Correlations between (A,B) oxygen saturation and (C,D) amino acid 
metabolism and functional capacity in all COPD patients. Statistics by Pearson 
correlation.       
Figure 5. Correlations between muscle function (Leg strength/Kg lean mass) and (A) 
Stroop Color Word Test performance (SCWT - Pt 3). (B) Trail making test performance 
(TMT- Pt B) in all COPD patients. Statistics by Pearson correlation.       
 
Table 1: Subject Characteristics 







Age (years) 66.6 (1.4) 68.4 (1.7) 61.8 (2.4) 71.6 (2.0) 
*p=0.055;# 
Gender (n, female/male) 13/15 20/17 8/4 12/13 




Fat Free Mass Index (kg/m2) 18.4 (0.6) 18.2 (0.5) 18.87 (1.0) 17.9 (0.6) 
Fat Mass Index (kg/m2) 8.7 (0.5) 10.3 (0.8) 12.1 (1.6)* 9.4 (0.9) 
#p=0.072 
Android fat (%) 35.3 (1.5) 36.2 (2.2) 41.6 (2.8) 33.6 (2.8) 
#p=0.052 
Gynoid fat (%) 34.1 (1.6) 35.6 (1.4) 39.5 (1.6) 
*p=0.067 
33.6 (1.9)# 
Charlson comorbidity index 
(score) 
0.38 (0.2) 1.61 (0.2)* 1.88 (0.3)* 1.47 (0.2)* 
Pulmonary function and COPD related measures 
FEV1 (% of predicted) 98.2 (2.5) 44.6 (2.6)*** 45.8 (4.6)*** 44.1 (3.2)*** 
FVC (% of predicted) 90.78 (2.1) 56.2 (2.3)*** 55.8 (3.2)*** 56.4 (3.2)*** 
FEV1/FVC (ratio) 89.1 (2.4) 57.4 (2.1)* 61.8 (3.8)* 55.3 (2.4)* 
Gold Stage (0-4) 0.00 (0.00) 2.8 (0.2)*** 2.8 (0.2)*** 2.8 (0.2)*** 
Oxygen saturation (%) 97.7 (0.2) 94.2 (0.6)*** 95.4 (0.5)* 93.7 (0.8)***; 
#p=0.103 
O2 use (n, yes/no) 0/28 17/20 4/8 13/12 
Dietary intake 
Total calories (kcal) 2063 (145) 1953 (106) 2021 (193) 1916 (129) 
Total fat intake (g) 89.4 (10.5) 81.5 (7.1) 84.2 (11.8) 80.0 (9.1) 
Total carbohydrate intake (g) 217.5 (19.0) 213.5 (14.5) 220.5 (24.0) 209.6 (18.5) 
Total fiber intake (g) 21.8 (2.2) 14.6 (1.3)** 14.9 (1.8)* 14.5 (1.7)** 
Total protein intake (g) 87.3 (7.0) 73.0 (4.9) 
*p=0.093 
73.7 (8.3) 72.7 (6.3) 
Protein intake (grams/kg/day) 1.1 (0.7) 0.97 (0.08) 0.88 (0.10) 1.0 (0.1) 
Data are mean (SE).  Statistics are by unpaired t-test or 1-way ANOVA. FEV1: Forced Expiratory Volume in 
one second. FVC: Forced Vital Capacity.  Android fat and gynoid fat correspond to central and peripheral fat 
distribution, respectively. * denotes difference from Healthy, p<0.05; # denotes difference from COPD 
functional,  p<0.05. 
  
 
Table 2 - Muscle function, cognitive performance and mood status 








Leg extension torque (Nm) 104.4 (6.1) 72.1 (4.4)* 94.2 (8.7) 61.5 (3.3)*# 
Leg extension force (N) 327.6 (17.8) 238.1 
(14.2)*** 
307.2 (31.4) 209.3 
(11.2)***## 
Leg extension force per kg lean mass 
(N/kg) 
6.5 (0.2) 4.9 (0.2)*** 6.1 (0.3) 4.5 
(0.2)***### 




Inspiratory muscle strength (cmH2O) 94.5 (7.1) 66.4 (4.9)** 78.5 (9.6) 60.9 (5.3)*** 
Expiratory muscle strength (cmH2O) 113.3 (7.7) 92.6 (5.2)* 100.1 (9.5) 89.5 (6.2)* 
PASE (score) 176.9 (18.0) 129.2 (10.3)* 141.6 (23.9) 122.5 (9.4)* 
Cognition 
SCWT: Part 1 time (Sec) 48.4 (1.5) 55.3 (2.5)* 52.3 (3.5) 56.7 (3.3)* 
SCWT: Part 2 time (Sec) 62.0 (2.2) 69.7 (2.8) 
*p=0.051 
67.1 (5.0) 70.9 (3.5)* 
SCWT: Part 3 time (Sec) 110.6 (4.6) 134.7 (6.8)* 123.1 (11.1) 140.1 (8.4)* 
SCWT: Interference (Sec) 55.4 (3.7) 72.2 (6.0)* 63.4 (9.4) 76.3 (7.6)* 
SCWT: Part 1 errors 0.04 (0.04) 0.46 (0.27) 0.18 (0.12) 0.58 (0.39) 
SCWT: Part 2 errors 0.29 (0.11) 0.66 (0.21) 0.82 (0.38) 0.58 (0.25) 
SCWT: Part 3 errors 0.96 (0.35) 4.7 (1.2)* 1.8 (1.0) 6.0 (1.6)**# 
TMT: Part A time (Sec) 27.3 (1.7) 35.7 (2.5)* 29.9 (3.2) 38.4 (3.2)* 
#p=0.082 
TMT: Part B time (Sec) 58.4 (3.8) 80.9 (6.3)* 68.0 (7.2) 87.0 (8.5)* 
HADS: Depression 2.9 (0.7) 5.9 (0.6)* 7.0 (1.2)* 5.3 (0.6)* 
HADS: Anxiety 4.0 (0.7) 5.8 (0.6) 
*p=0.061 
7.8 (1.2)* 4.7 (0.6)# 
Data are mean (SE).  Statistics are by unpaired t-test or 1-way ANOVA. SCWT: Stroop Color Word Test. SCWT 
Interference: (Part 3-((Part 1+Part2)/2). TMT: Trail Making Test. HADS: Hospital Anxiety and Depression 
Scale. PASE: physical activity questionnaire for the elderly. * denotes difference from Healthy, p<0.05; # 
















Table 3: Plasma concentrations  








Amino and keto acids (μmol/l)     
tau-methylhistidine 4.7 (0.3) 4.4 (0.3) 4.1 (0.5) 4.5 (0.4) 
Valine 173.2 (7.5) 157.3 (6.7) 159.6 (10.4) 156.2 (8.8) 
Isoleucine 54.3 (2.5) 55.4 (2.6) 51.9 (4.0) 57.2 (3.3) 
Leucine 95.9 (4.0) 87.7 (3.9) 84.1 (4.8) 89.6 (5.5) 
BCAAsum 323.3 (13.1) 300.4 (12.6) 295.6 (18.0) 303.0 (16.9) 
Tryptophan 35.9 (1.5) 35.2 (1.1) 37.9 (1.3) 33.9 (1.5) 
Phenylalanine 43.6 (1.48) 44.8 (1.6) 43.7 (2.0) 45.3 (2.2) 
Tyrosine 48.6 (2.4) 48.0 (2.0) 50.4 (2.4) 49.8 (2.8) 
Glycine 224.1 (15.6) 226.8 (13.3) 226.8 (13.3) 235.7 (15.7) 
Glutamate 49.0 (5.4) 40.1 (4.2) 43.4 (5.7) 38.4 (5.7) 
Essential amino acids sum 746.8 (24.4) 724.5 (22.7) 716.3 (25.2) 728.7 (32.2) 
α-ketoisocaproic acid (KIC) 26.5 (2.1) 26.2 (1.7) 26.1 (2.9) 26.3 (2.1) 
α-ketoisovalerate (KIV) 14.0 (0.7) 13.1 (0.7) 12.6 (1.1) 13.3 (0.9) 
α-keto-β-methylvalerate (KMV) 14.4 (1.3) 15.2 (1.0) 14.8 (1.7) 15.3 (1.3) 
BCKAsum 45.5 (2.9) 54.5 (3.2) 53.6 (5.4) 55.0 (4.1) 
β-hydroxy β-methylbutyrate 
(HMB) 
2.2 (0.2) 2.1 (0.2) 1.8 (0.3) 2.2 (0.3) 
Clinical markers     
Glucose (mmol/L) 5.5 (0.1) 5.8 (0.2) 6.1 (0.3)* 5.6 (0.2) 
*p=0.097 
High sensitive C-Reactive 
Protein (mg/L) 
1.2 (0.3) 5.7 (1.3)** 6.8 (2.9)* 5.2 (1.3)* 
Data are mean (SE).  Statistics are by unpaired t-test or 1-way ANOVA. BCAAsum = Sum of the branched-
chain amino acids valine, isoleucine and leucine. BCKAsum = Sum of the branched-chain keto acids α-
ketoisocaproic acid, α-ketoisovalerate and α-keto-β-methylvalerate. * denotes difference from Healthy, 
p<0.05; # denotes difference from COPD functional group,  p<0.05 
 
Table 4: Whole body production of amino and keto acids 








Glutamate 172.3 (17.7) 221.8 (25.3) 263.5 (60.9) 203.7 (25.0) 
Glutamine 408.9 (29.1) 392.5 (24.6) 398.8 (41.9) 389.1 (31.1) 
Glycine 191.5 (14.7) 187.7 (12.7) 185.7 (24.9) 188.7 (14.8) 
Citrulline 14.2 (0.8) 16.7 (0.9)* 16.2 (1.3) 17.0 (1.2) 
*p=0.055 
Arginine 81.0 (6.0) 102.7 (6.4)* 107.1 (10.0)* 100.5 (8.3) 
*p=0.065 
tau-methylhistidine 0.77 (0.10) 0.86 (0.06) 0.86 (0.10) 0.87 (0.07) 
Leucine 96.3 (4.7) 115.7 (5.2)* 113.3 (8.8) 116.9 (6.5)* 
Phenylalanine 73.4 (5.4) 64.0 (3.9) 65.1 (6.8) 63.5 (4.9) 
Tyrosine 56.5 (3.7) 52.2 (2.8) 54.4 (4.8) 51.0 (3.6) 
Tryptophan 10.5 (0.8) 9.8 (0.5) 10.6 (0.9) 9.4 (0.6) 
α-ketoisocaproic acid (KIC) 13.3 (1.7) 17.2 (2.0) 13.8 (1.8) 18.6 
(2.7)*p=0.093 
Data are in µmol/kg ffm/h, mean (SE). Statistics are by unpaired t-test or 1-way ANOVA. * denotes 
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Figure 1. Overview of study design. Cognitive testing: executive functioning 
and psychomotor speed. Questionnaires: physical activity, mood status, dietary 
recall. Muscle dynamometry: upper and lower limb muscle strength.
Blood sampling
*IV pulse: 



















































































































































































Figure 4. Correlations between (A,B) oxygen saturation and (C,D) amino acid
metabolism and functional capacity in all COPD patients. Statistics by
Pearson correlation.














































s r: 0.4889, p<0.01
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Figure 5. Correlations between muscle function (Leg strength/Kg lean mass) and
(A) Stroop Color Word Test performance (SCWT - Pt 3). (B) Trail making test
performance (TMT- Pt B) in all COPD patients. Statistics by Pearson correlation.
Healthy COPD
functional
COPD
dysfunctional
0
50
100
150
F
E
V
1
[%
pr
ed
]
✱✱✱✱
✱✱✱✱
B
Healthy COPD
functional
COPD
dysfunctional
0
2
4
6
8
A
S
M
I[
kg
/m
2 ]
A
Healthy COPD
functional
COPD
dysfunctional
0
2
4
6
8
Le
g
S
tr
en
gt
h/
K
g
Le
an
M
as
s
****
###
C
Healthy COPD
functional
COPD
dysfunctional
0
50
100
150
200
S
C
W
T
-
P
t3
[S
e
c]
**
A
Healthy COPD
functional
COPD
dysfunctional
0.0
0.5
1.0
1.5
S
C
W
T
-
P
t.
3
[#
e
rr
o
rs
]
**
#
B
Healthy COPD
functional
COPD
dysfunctional
0
10
20
30
40
50
T
M
T
-
P
tA
[S
ec
]
*
0.08
C
Healthy COPD
functional
COPD
dysfunctional
0
25
50
75
100
125
150
T
M
T
-
P
t
B
[S
e
c]
**
D
